Skip to main content
. 2017 Apr 27;17:294. doi: 10.1186/s12885-017-3279-4

Table 5.

Univariate/multivariate analyses of factors associated with prognosis in the p-DCS group

Univariate analysis Multivariate analysis
Variable No. of patients HR 95% CI P value HR 95% CI P value
Age (years) ≥70 15 1.470 (0.607–3.560) 0.393
<70 24
Gender Male 32 0.409 (0.156–1.075) 0.070 0.281 (0.093–0.846) 0.024
Female 7
ECOG performance status ≥1 2 0.894 (0.119–6.698) 0.913
0 37
Borrmann macroscopic type Non-type 4 38 0.452 (0.059–3.439) 0.443
Type 4 1
Differentiation Diffuse 18 0.758 (0.310–1.854) 0.543
Intestinal 21
PAN metastasis (+) 16 1.869 (0.539–4.854) 0.201
(−) 23
Hepatic metastasis (+) 9 2.508 (0.993–6.333) 0.052 1.718 (0.530–5.570) 0.367
(−) 30
RECIST SD, PD 10 1.769 (0.705–4.439) 0.225
CR, PR 29
Histological evaluation 0, 1a, 1b 17 2.84 (1.152–7.000) 0.023 1.938 (0.612–6.129) 0.260
2, 3 22
CD42b expression ≥10% 24 3.644 (1.213–10.95) 0.021 4.406 (1.325–14.65) 0.016
<10% 15
Podoplanin expression (+) 28 1.411 (0.512–3.889) 0.505
(−) 11
SNAIL expression (+) 30 1.736 (0.664–4.539) 0.261
(−) 9
FOXP3 expression (+) 7 1.272 (0.369–4.386) 0.703
(−) 32

CI confidence interval, CR complete response, ECOG Eastern Cooperative Oncology Group, FOXP3 forkhead box P3, HR hazard ratio, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria in Solid Tumors, SD stable diseases